Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 9/20 | 0.44 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508405 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8089855 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL3688851 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL30660637 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1250920 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23622224 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL15081440 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19102018 | 0.83 | CA1 (0.52) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL305895 | 0.82 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL10652 | 0.79 | CA1 (0.57) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115175738-A | Conjugates undergoing intramolecular rearrangement | 阿森迪斯药物股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-1596845-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | Genfit (FR) | 2005-11-23 | — | — | EP | disclosed |
| US-6958141-B2 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2005-10-25 | — | — | US | disclosed |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2004-09-30 | — | — | US | disclosed |
| WO-2004073698-A1 | THERAPEUTIC USE OF ACYL GLYCEROLS AND THE NITROGEN- AND SULPHUR-CONTAINING ANALOGUES THEROF | GENFIT (FR) | 2004-09-02 | — | — | WO | disclosed |
| US-6699458-B2 | CELL MEMBRANE PERMEABILITIES GREATER THAN THAT OF SUCROSE | BRACCO INTERNATIONAL B.V. (NL) | 2004-03-02 | — | — | US | disclosed |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | BRACCO SUISSE SA (CH) | 2004-01-15 | — | — | US | disclosed |
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO SUISSE SA (CH) | 2002-05-09 | — | — | US | disclosed |
| US-6359120-B1 | REACTING ALKYLENE DIAMINE WITH HALOKETONE TO PROVIDE AN ALKYLENE DIAMINEDIKETONE WHICH IS CONVERTED TO ALKYLENE DIAMINEDIOXIME; OR REACTING ALKYLENE DIAMINE WITH FIRST HALOKETONE AND REACTING WITH SECOND HALOKETONE | BRACCO INTERNATIONAL B.V. (NL) | 2002-03-19 | — | — | US | disclosed |
| EP-1012139-A4 | AZETIDINONE DERIVATIVES AS $g(b)-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2001-08-16 | — | — | EP | disclosed |
| US-6184361-B1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 2001-02-06 | — | — | US | disclosed |
| EP-1012139-A1 | AZETIDINONE DERIVATIVES AS $g(b)-LACTAMASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999010324-A1 | AZETIDINONE DERIVATIVES AS β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 1999-03-04 | — | — | WO | disclosed |
| US-5808091-A | DIAGNOSTIC IMAGING AGENT | BRACCO INTERNATIONAL B.V. | 1998-09-15 | — | — | US | disclosed |
| US-5688487-A | Diagnostic imaging methods using rhenium and technetium complexes containing a hypoxia-localizing moiety | BRACCO INTERNATIONAL B.V. (NL) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020054853-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | CA1 22/4885CA2 79/4885CA7 111/4885 |
| US-20040191174-A1 | Rhenium and technetium complexes containing a hypoxia-localizing moiety | HIF1A, HIF1AN, SLC2A8 | CA1 22/4885CA2 79/4885CA7 111/4885 |
| US-20040010127-A1 | RHENIUM AND TECHNETIUM COMPLEXES CONTAINING A HYPOXIA-LOCALIZING MOIETY | HIF1A, HIF1AN, SLC2A8 | CA1 22/4885CA2 79/4885CA7 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.